Passage Bio Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 101
- Market Cap
- $45.8M
- Website
- http://www.passagebio.com
Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease
Phase 1
Suspended
- Conditions
- Leukodystrophy, Globoid Cell
- Interventions
- Biological: PBKR03
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Passage Bio, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04771416
- Locations
- 🇨🇦
Montreal Children's Hospital, Montréal, Canada
🇬🇧Manchester University, Manchester, United Kingdom
🇺🇸New York-Presbyterian, New York, New York, United States
A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)
Phase 1
Recruiting
- Conditions
- Frontotemporal DementiaFTD-GRNFTDDementia Frontotemporal
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Passage Bio, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04747431
- Locations
- 🇵🇹
Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
🇮🇹Besta Institute, Milan, Italy
🇧🇷Hospital das Clinicas da Universidade Federal de Minas Gerais (UFMG), Minas Gerais, Brazil
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis
Phase 1
Active, not recruiting
- Conditions
- Beta-Galactosidase-1 (GLB1) DeficiencyGM1 Gangliosidosis, Type IGM1 Gangliosidosis, Type 2GM1 Gangliosidosis
- Interventions
- Biological: PBGM01
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Passage Bio, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04713475
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇨🇦The Hospital for Sick Children, Toronto, Canada
🇧🇷Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil
© Copyright 2025. All Rights Reserved by MedPath